Tags

Type your tag names separated by a space and hit enter

Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
Int J Antimicrob Agents. 2020 Jun; 55(6):105982.IJ

Abstract

• Discussion of the role of immunomodulatory agents to reduce the cytokine storm in severe cases of COVID-19. • Potential immunomodulatory agents currently used in the treatment of COVID-19 (chloroquine, hydroxychloroquine and tocilizumab) are discussed. • Other immunomodulatory agents with good safety profiles may be considered for use in combination with antiviral drugs for the treatment of severe or critical cases of COVID-19.

Links

PMC Free PDF

Authors+Show Affiliations

Zhao M
Department of Pharmacy, Beijing Hospital, National Centre of Gerontology, Beijing, P.R. China; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, P.R. China. Electronic address: zhaoming4287@bjhmoh.cn.

MeSH

Antibodies, Monoclonal, HumanizedAntiviral AgentsBetacoronavirusCOVID-19ChloroquineCoronavirus InfectionsCytokinesHumansHydroxychloroquineImmunomodulationImmunotherapyInterleukin-6PandemicsPneumonia, ViralSARS-CoV-2

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32305588

Citation

Zhao, Ming. "Cytokine Storm and Immunomodulatory Therapy in COVID-19: Role of Chloroquine and anti-IL-6 Monoclonal Antibodies." International Journal of Antimicrobial Agents, vol. 55, no. 6, 2020, p. 105982.
Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020;55(6):105982.
Zhao, M. (2020). Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. International Journal of Antimicrobial Agents, 55(6), 105982. https://doi.org/10.1016/j.ijantimicag.2020.105982
Zhao M. Cytokine Storm and Immunomodulatory Therapy in COVID-19: Role of Chloroquine and anti-IL-6 Monoclonal Antibodies. Int J Antimicrob Agents. 2020;55(6):105982. PubMed PMID: 32305588.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. A1 - Zhao,Ming, Y1 - 2020/04/16/ PY - 2020/3/6/received PY - 2020/4/5/revised PY - 2020/4/7/accepted PY - 2020/4/20/pubmed PY - 2020/6/17/medline PY - 2020/4/20/entrez KW - COVID-19 KW - Chloroquine KW - Cytokine storm KW - Hydroxychloroquine KW - Tocilizumab SP - 105982 EP - 105982 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 55 IS - 6 N2 - • Discussion of the role of immunomodulatory agents to reduce the cytokine storm in severe cases of COVID-19. • Potential immunomodulatory agents currently used in the treatment of COVID-19 (chloroquine, hydroxychloroquine and tocilizumab) are discussed. • Other immunomodulatory agents with good safety profiles may be considered for use in combination with antiviral drugs for the treatment of severe or critical cases of COVID-19. SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/32305588/Cytokine_storm_and_immunomodulatory_therapy_in_COVID_19:_Role_of_chloroquine_and_anti_IL_6_monoclonal_antibodies_ DB - PRIME DP - Unbound Medicine ER -